Evaluation of Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine in Adults With Good General Health

You may be eligible if

• Inclusion:
• Good general health
• ≥18 years of age on the day of screening and are ≤50 years of age on the day of IP administration
• Adherence to the requirements of the protocol and the follow-up for the planned duration of the study
• Undergo HIV testing, risk reduction counseling, and receive HIV test results
• As applicable use male or female condoms for 1 month following IP administration
• Use an effective method of contraception from at least 2 weeks before and continue until 3 months following receipt of vaccine
• As applicable undergo urine pregnancy tests
• Forgo donation of blood or any other tissues throughout the course of the study
• Exclusion:
• Any clinically relevant abnormality
• Any clinically significant acute or chronical medical condition
• Women who are pregnant or breastfeeding
• Bleeding disorder
• Infectious disease
• History of splenectomy
• Receipt of any vaccine within the previous 28 days or planned receipt within 28 days after vaccination with IP.
• Receipt of blood transfusion or blood-derived products within 3 months prior to screening
• Prior exposure to SEBOV or history of any hemorrhagic fever
• Prior receipt of any VSV-vectored vaccine
• Receipt of another IP within 3 months prior to enrollment or expected participation during this study.
• Prior receipt of another Sudan Ebola vaccine or receipt of polyclonal or monoclonal antibodies directed against Sudan Ebola in the past 6 months
• History of severe reactogenicity to vaccines or severe allergy to food or medications
• A history of malignancy in the past 5 years (prior to screening) or ongoing malignancy.
• Serious infections requiring antibiotic, antiviral, or antifungal therapy within 30 days prior to enrollment
• Body mass index (BMI) ≥35
• Current or planned occupational or household contact from screening through 3 months after vaccine administration with any immunocompromised individual